Imipenem

Generic Name: Imipenem

Brand Names: Primaxin, Recarbrio

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₃O_₄S

CAS Number: 64221-86-9

Unique Ingredient Identifier: Q20IM7HE75

Background: Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ert...

Indication: Imipenem is indicated, in combination with cilastatin with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.

Associated Conditions: Bacterial Septicemia, Bone and Joint Infections, Complicated Intra-Abdominal Infections (cIAIs) caused by Gram-negative Bacteria, Complicated Urinary Tract Infection, Complicated Urinary Tract Infection caused by Gram-negative Bacteria, Endocarditis caused by staphylococcus aureus, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Nosocomial Pneumonia caused by Gram-negative Bacteria, Pyelonephritis, Skin and Subcutaneous Tissue Bacterial Infections, Uncomplicated Urinary Tract Infections, Ventilator Associated Bacterial Pneumonia caused by Gram-negative Bacteria

Associated Therapies: -

Clinical Trials

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Phase 2

Recruiting

Conditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)

Interventions: Drug: Amikacin
Drug: Tigecycline
Drug: Imipenem
Drug: Cefoxitin
Drug: Linezolid
Drug: Azithromycin
Drug: co-trimoxazole
Drug: Clarithromycin
Drug: Clofazimine
Drug: Doxycycline
Drug: Moxifloxacin
Drug: Ethambutol
Drug: Bedaquiline
Drug: Rifabutin

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-11

Lead Sponsor: The University of Queensland

Target Recruit Count: 300

Registration Number: NCT04310930

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Not Applicable

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Imipenem
Drug: Tigecycline
Drug: GMCSF
Drug: Colistin

First Posted Date: 2019-12-23

Last Posted Date: 2021-02-16

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 90

Registration Number: NCT04208763

Locations: 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

Conditions: Critical Illness
Bacterial Infections

Interventions: Drug: Meropenem
Drug: Imipenem

First Posted Date: 2019-02-28

Last Posted Date: 2020-05-01

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 102

Registration Number: NCT03858387

Locations: 🇹🇭
Faculty of Medicine, Prince of Songkla University, Thailand, Hat Yai, Songkla, Thailand

Imipenem in Critically Ill Patients

Phase 4

Conditions: Critically Ill Patients With ECMO

Interventions: Drug: Imipenem

First Posted Date: 2018-12-14

Last Posted Date: 2019-02-15

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 12

Registration Number: NCT03776305

Locations: 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand